$1,351.12
Value $1.27T
LLY and UTHR stock compared: price, dividend, valuation and results, from SEC filings.
$1,351.12
Value $1.27T
$559.10
Value $24.5B
Eli Lilly and Company (LLY) has a market value of $1.27T and United Therapeutics (UTHR) $24.5B. Over the last year, with dividends, LLY moved +32.0% and UTHR +17.3%. The P/E is 46.2 for LLY and 19.9 for UTHR. Dividend yield: LLY 0.47%, UTHR none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LLY$1.27T
UTHR$24.5B
LLY is 52 times UTHR
Revenue, 12 months
LLY$86.5B
UTHR$3.2B
LLY is 27 times UTHR
Net income, 12 months
LLY$27.6B
UTHR$1.2B
LLY is 22 times UTHR
Operating margin
LLY–
UTHR41.4%
ROIC
LLY35.5%
UTHR–
P/E
LLY46.2
UTHR19.9
LLY is 2.3 times UTHR
Dividend yield
LLY0.5%
UTHR0.0%
0.5 points apart
5-year return
LLY+439.8%
UTHR+175.9%
263.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LLY+439.8%
UTHR+176.0%
| Period | LLYWith dividends | UTHRWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +32.0%Price +31.2% | +17.3%Price +17.3% |
| 3 years since November 17, 2023 | +132.9%+32.6% a yearPrice +128.3% | +144.2%+34.7% a yearPrice +144.2% |
| 5 years since November 18, 2021 | +439.8%+40.1% a yearPrice +417.0% | +175.9%+22.5% a yearPrice +175.9% |
| 10 years since November 21, 2016 | +1,950.7%+35.3% a yearPrice +1,662.9% | +325.3%+15.6% a yearPrice +325.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LLYEli Lilly and CompanyUTHRUnited Therapeutics
| Price | $1,351.12 | $559.10 |
|---|---|---|
| Market value | $1.27T | $24.5B |
| Enterprise value (EV) | $1.32T | – |
| P/E | 46.2 | 19.9 |
| P/E, 5-year median | 49.9 | 17.5 |
| P/B | 31.7 | 3.9 |
| EV/EBIT | 37.9 | – |
| Free cash flow yield | 1.5% | 3.5% |
| Revenue, 12 months | $86.5B | $3.2B |
|---|---|---|
| Net income, 12 months | $27.6B | $1.2B |
| Free cash flow, 12 months | $19.7B | $867M |
| Earnings per share, 12 months | $30.81 | $26.49 |
| Revenue growth, year on year | 44.7% | 10.6% |
| Revenue growth a year, past | +21.6%over 5 years | +16.5%over 5 years |
| EPS growth a year, past | +27.6%over 5 years | +19.3%over 5 years |
| Gross margin | 83.6% | 86.3% |
|---|---|---|
| Operating margin | – | 41.4% |
| Net margin | 31.9% | 38.6% |
| ROIC | 35.5% | – |
| ROE | 88.6% | 19.1% |
| Cash | $4.9B | $2.1B |
|---|---|---|
| Total debt | $49.5B | – |
| Net debt / EBITDA | 1.2 | – |
| Interest cover | 38.9× | 111.0× |
| Dividend yield | 0.5% | – |
|---|---|---|
| Dividend per share, 12 months | $6.34 | – |
| Dividend growth a year, past | +15.2%over 5 years | – |
| Buyback yield | 0.3% | 4.1% |
| Shareholder yield | 0.8% | 4.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.27T) is about 52.0 times United Therapeutics ($24.5B), at today's prices.
Since November 21, 2016, LLY's price moved +1,662.9% and UTHR's +325.3%. With dividends: LLY +1,950.7% (+35.3% a year), UTHR +325.3% (+15.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for United Therapeutics. Over the last twelve months they paid $6.34 and – per share.
At today's price, the P/E is 46.2 for LLY and 19.9 for UTHR. The median of the last five years was 49.9 and 17.5, which shows where each stands against its own past.
Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and 38.6% for United Therapeutics, and the operating margin – and 41.4%. Revenue was $86.5B and $3.2B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.